Your browser doesn't support javascript.
Clinical Outcome Prediction in COVID-19 Patients by Lymphocyte Subsets Analysis and Monocytes' iTNF-α Expression.
Madonna, Gabriele; Sale, Silvia; Capone, Mariaelena; De Falco, Chiara; Santocchio, Valentina; Di Matola, Tiziana; Fiorentino, Giuseppe; Pirozzi, Caterina; D'Antonio, Anna; Sabatino, Rocco; Atripaldi, Lidia; Atripaldi, Umberto; Raffone, Marcello; Curvietto, Marcello; Grimaldi, Antonio Maria; Vanella, Vito; Festino, Lucia; Scarpato, Luigi; Palla, Marco; Spatarella, Michela; Perna, Francesco; Cerino, Pellegrino; Botti, Gerardo; Parrella, Roberto; Montesarchio, Vincenzo; Ascierto, Paolo Antonio; Atripaldi, Luigi.
  • Madonna G; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy.
  • Sale S; UOC Biochimica Clinica, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
  • Capone M; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy.
  • De Falco C; UOC Biochimica Clinica, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
  • Santocchio V; UOC Biochimica Clinica, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
  • Di Matola T; UOC Biochimica Clinica, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
  • Fiorentino G; UOC Fisiopatologia e Riabilitazione Respiratoria, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
  • Pirozzi C; UOC Biochimica Clinica, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
  • D'Antonio A; UOC Biochimica Clinica, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
  • Sabatino R; UOC Biochimica Clinica, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
  • Atripaldi L; Dipartimento di Scienze Mediche Traslazionali, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
  • Atripaldi U; Dipartimento di Scienze Mediche Traslazionali, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
  • Raffone M; UOC Microbiologia e Virologia, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
  • Curvietto M; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy.
  • Grimaldi AM; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy.
  • Vanella V; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy.
  • Festino L; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy.
  • Scarpato L; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy.
  • Palla M; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy.
  • Spatarella M; UOSD di Farmacia, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
  • Perna F; Dipartimento di Medicina Clinica e Chirurgia, Università degli Studi di Napoli "Federico II", 80131 Naples, Italy.
  • Cerino P; Istituto Zooprofilattico Sperimentale del Mezzogiorno, 80055 Portici, Italy.
  • Botti G; Scientific Direction, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy.
  • Parrella R; UOC Malattie Infettive ad Indirizzo Respiratorio, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
  • Montesarchio V; UOC Oncologia, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
  • Ascierto PA; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy.
  • Atripaldi L; UOC Biochimica Clinica, AORN Ospedali dei Colli-Monaldi-Cotugno-CTO, 80131 Napoli, Italy.
Biology (Basel) ; 10(8)2021 Aug 01.
Article in English | MEDLINE | ID: covidwho-1376731
ABSTRACT
In December 2019, a novel coronavirus, "SARS-CoV-2", was recognized as the cause of coronavirus disease 2019 (COVID-19). Several studies have explored the changes and the role of inflammatory cells and cytokines in the immunopathogenesis of the disease, but until today, the results have been controversial. Based on these premises, we conducted a retrospective assessment of monocyte intracellular TNF-α expression (iTNF-α) and on the frequencies of lymphocyte sub-populations in twenty-five patients with moderate/severe COVID-19. We found lymphopenia in all COVID-19 infected subjects compared to healthy subjects. On initial observation, in patients with favorable outcomes, we detected a high absolute eosinophil count and a high CD4+/CD8+ T lymphocytes ratio, while in the Exitus Group, we observed high neutrophil and CD8+ T lymphocyte counts. During infection, in patients with favorable outcomes, we observed a rise in the lymphocyte count, in the monocyte and in Treg lymphocyte counts, and in the CD4+ and in CD8+ T lymphocytes count but a reduction in the CD4+/CD8+ T lymphocyte ratio. Instead, in the Exitus Group, we observed a reduction in the Treg lymphocyte counts and a decrease in iTNF-α expression. Our preliminary findings point to a modulation of the different cellular mediators of the immune system, which probably play a key role in the outcomes of COVID-19.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Language: English Year: 2021 Document Type: Article Affiliation country: Biology10080735

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Language: English Year: 2021 Document Type: Article Affiliation country: Biology10080735